• 16 May 2013

    Human Clinical Efficacy Data for ChromaDex's Patented pTeroPure (pterostilbene) to be Presented at American Heart Association's High Blood Pressure Research 2012 Scientific Sessions

    IRVINE, Calif. and OXFORD, Miss.
    ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries announced today that the human clinical data for its patented pTeroPure (pterostilbene) study was accepted for presentation at the High Blood Pressure Research 2012 Scientific Sessions, sponsored by the American Heart Association's Council for High Blood Pressure Research and Council on Kidney in Cardiovascular Disease. The presentation will be September 20, 2012, in Washington, D.C.